Caribou Biosciences (CRBU)
(Delayed Data from NSDQ)
$2.16 USD
+0.05 (2.37%)
Updated Aug 30, 2024 03:59 PM ET
After-Market: $2.16 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Price, Consensus and EPS Surprise
CRBU 2.16 +0.05(2.37%)
Will CRBU be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CRBU based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CRBU
Caribou Biosciences, Inc. (CRBU) Reports Q2 Loss, Tops Revenue Estimates
Caribou Biosciences, Inc. (CRBU) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
CRBU: What are Zacks experts saying now?
Zacks Private Portfolio Services
Caribou Biosciences, Inc. (CRBU) Reports Q1 Loss, Misses Revenue Estimates
All You Need to Know About Caribou Biosciences, Inc. (CRBU) Rating Upgrade to Buy
Caribou Biosciences, Inc. (CRBU) Upgraded to Buy: What Does It Mean for the Stock?
Other News for CRBU
Caribou Biosciences to Participate in Upcoming Investor Conferences
Caribou Biosciences Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
Caribou Biosciences: A Strong Buy on Solid Financials and Promising Trials
Caribou Biosciences Appoints Tina Albertson, MD, PhD, as Chief Medical Officer
Caribou Biosciences Ltp appoims Albertso as CMO